Search Results

VentureMed Names Jordan Knepper as CMO and Announces Study Results for Flex VP System

March 14, 2025—VentureMed Group, Inc., a medical device company focused on arteriovenous access and peripheral arterial disease, recently announced the appointment of Jordan Knepper, MD, as Chief Medical Officer.

Infinity Angioplasty Balloon Catheter Receives 510(k) Clearance

June 16, 2020—Infinity Angioplasty Balloon Co., LLC announced that the FDA has cleared the Infinity angioplasty balloon catheter for percutaneous transluminal angioplasty treatment of peripheral arterial disease in the peripheral vasculature, including iliac, femoral, popliteal, and infrapopliteal arteries, and for the treatment of arteriovenous dialysis fistulas.

Avinger Begins VISION Trial of the Pantheris Catheter

July 14, 2014—Avinger Inc. announced that enrollment has commenced in the VISION trial to evaluate the company’s Pantheris catheter for the treatment of peripheral artery disease.

CE Mark Approved for Avinger's Wildcat Catheter

May 12, 2011—Avinger, Inc. (Redwood City, CA) announced that it has received CE Mark approval for the Wildcat catheter to be used in endovascular procedures for treating peripheral artery disease.

FDA Clears Avinger's Wildcat Catheter for CTO Treatment

August 16, 2011—Avinger, Inc. (Redwood City, CA) has received 510(k) clearance from the US Food and Drug Administration to market its Wildcat catheter for crossing chronic total occlusions (CTOs) to allow treatment via balloon angioplasty, stent, or atherectomy for peripheral artery disease.

FDA Clears VentureMed's Flex Scoring Catheter

June 7, 2016—VentureMed Group, Ltd. announced receipt of US Food and Drug Administration (FDA) 510(k) clearance for the Flex scoring catheter, an endovascular device that precisely and dynamically scores any length of atherosclerotic lesion as it passes through the femoral-popliteal anatomy.